SEC Form 4 · accession 0001209191-16-130208
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jun 29, 2016
Accepted (ET)
Jun 30, 2016 · 3:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2016 | M | 5,130 | $35.35 | A | 273,355 | D | |
| Common StockF2,F3 | Jun 29, 2016 | S | 1,000 | $83.53 | D | 272,355 | D | |
| Common StockF2,F4 | Jun 29, 2016 | S | 1,100 | $84.68 | D | 271,255 | D | |
| Common StockF2,F5 | Jun 29, 2016 | S | 3,030 | $85.29 | D | 268,225 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401k | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $35.35 | Jun 29, 2016 | M | 5,130 | D | — | Jul 19, 2016 | Common Stock | 5,130 | 5,140 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $83.53 (range $82.99 to $83.96).
- F4Open market sales reported on this line occurred at a weighted average price of $84.68 (range $84.02 to $85.01).
- F5Open market sales reported on this line occurred at a weighted average price of $85.29 (range $85.02 to $85.87).
- F6Fully vested.